Female Contraceptive Market to Grow with a CAGR of 6.24% through 2028
Factors such as women and couples prioritizing family
planning and reproductive health is expected to drive the Global Female
Contraceptive Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Female
Contraceptive Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Female Contraceptive Market
stood at USD 15.01 Billion in 2022 and is anticipated to grow with a CAGR of 6.24%
in the forecast period, 2024-2028. This can be attributed to government initiatives
and support. Many governments worldwide have recognized the importance of
family planning in controlling population growth and improving public health.
Consequently, they have implemented policies and programs to promote and
subsidize contraceptives, making them more affordable and accessible to a
broader population.
Furthermore, personalized medicine is making its way
into the female contraceptive market, allowing healthcare providers to tailor
contraceptive recommendations based on an individual's unique health profile
and preferences. Genetic testing and advanced screening techniques can help
identify which contraceptive methods are most suitable for a woman, minimizing
the risk of adverse effects and improving overall satisfaction.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Female Contraceptive Market.”
Several factors are driving market growth, including a
rise in sexually transmitted diseases (STDs), an increased rate of unintended
pregnancies, and the implementation of government initiatives. Globally, the
number of unintended pregnancies is on the rise, with significant global
implications. For example, according to the United Nations Population Fund, as
of March 2022, approximately half of all pregnancies worldwide are unintended,
totaling 121 million annually. More than 60% of these unplanned pregnancies
result in abortions, with an estimated 45% of all abortions categorized as
unsafe, leading to 5%–13% of all maternal fatalities and jeopardizing progress
toward the "Sustainable Development Goals." Additionally, a study
published in BMC Pregnancy and Childbirth in 2021 by Nebamallika Dahingia found
that unintended pregnancies impact roughly 85 million women globally, with
India accounting for more than one in seven of these cases. Uttar Pradesh,
India's most populous state, with a population of approximately 200 million,
exhibits a higher rate of unwanted fertility compared to the rest of the
country. Consequently, the increasing incidence of unintended pregnancies is
anticipated to drive growth in the female contraceptive market.
Furthermore, the escalating prevalence of STDs among
the population is expected to contribute to market growth. For instance, data
published by the World Health Organization in November 2021 revealed that in
2020, there were approximately 374 million new infections of four major
sexually transmitted diseases: chlamydia (129 million), gonorrhea (82 million),
syphilis (7.1 million), and trichomoniasis (156 million). Consequently, the
growing burden of STDs is expected to heighten the demand for contraception to
prevent disease transmission, thereby stimulating market growth.
Moreover, various countries and their respective
governments have recognized the need to address the increasing rates of
unintended pregnancies, launching numerous initiatives aimed at educating and
preventing unwanted abortions and pregnancies. Contraceptive pill usage is one
such initiative, and it is supported by the fundamental right to privacy
guaranteed by the United States Constitution. For example, the United States
Agency for International Development (USAID) promotes and backs voluntary
family planning and reproductive health programs in approximately 40 countries
worldwide. Consequently, government initiatives are fostering the adoption of
contraceptive methods to prevent unnecessary births and abortions.
Nevertheless, the female contraceptive market may face
constraints in the form of the high cost of devices and treatment, as well as
potential side effects associated with contraceptive drugs and devices, which
could impede market growth in the forecast period.
The Global Female Contraceptive Market is segmented
into contraceptive drugs, device, regional distribution, and company.
Based on device, the sub-dermal contraceptive implants
segment is expected to witness significant growth in the female contraceptive
market owing to the factors such as rising unwanted pregnancies, high clinical
effectiveness, and high adoption rate among the population. There are two types
of sub-dermal implants - Etonogestrel Implant, Levonorgestrel Implant. Under
sub-dermal contraceptive implants, the Etonogestrel implants are likely to
witness significant growth. Etonogestrel is a hormone that prevents ovulation.
This medication also causes changes in the cervical mucus and uterine lining,
making it harder for sperm to reach the uterus and harder for a fertilized egg
to attach to the uterus. Subdermal Etonogestrel implant is used as
contraception to prevent pregnancy. The medicine is contained in a small
plastic rod that is implanted under the skin of the upper arm. The medicine is
released slowly into the body. The rod can remain in place and provide
continuous contraception for up to 3 years.
The increasing company focus on adopting various
business strategies such as product launches, listing products in the
countries, mergers, and company spin-offs are likely to boost the growth of the
market over the forecast period.
Based on region, North America is projected to
maintain its dominance in the female contraceptive devices market throughout
the forecast period, primarily due to several factors. These include the
increasing instances of unintended pregnancies and high abortion rates, the
presence of advanced healthcare infrastructure, a high rate of adoption of
contraceptive drugs and devices, and a growing number of government
initiatives. A significant portion of the female population in the United
States and Canada falls within the reproductive age group. Consequently, the
rising occurrences of unwanted pregnancies and abortion rates play a pivotal
role in propelling market expansion in the region. For instance, data from the
Guttmacher Institute in March 2022 revealed that between 2015 and 2019, North
America witnessed a total of 5,660,000 pregnancies annually, with 2,590,000 of
them being unwanted, and 886,000 resulting in abortion. Moreover, statistics
published by the Pew Research Center in June 2022 showed an increase in
abortion cases, with 930,160 recorded in the United States in 2020 compared to
916,460 in 2019. This surge in abortion cases is anticipated to drive the
demand for various contraceptive methods to prevent unwanted pregnancies,
thereby fueling market growth.
Major companies operating in
Global Female Contraceptive Market are:
- Bayer AG
- Mayer Laboratories Inc
- Pfizer Inc
- Mylan Pharmaceuticals Inc
- Teva Pharmaceutical Industries Ltd
- Organon & Co.
- Agile Therapeutics Inc
- Lupin Pharmaceuticals Inc
- The Female Health Company
- FUJI LATEX CO.,LTD.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global female contraceptive market is undergoing
a transformation driven by innovation, technology, and evolving societal needs.
The upcoming key trends in the market encompass a wide range of options, from
reducing side effects and expanding non-hormonal alternatives to incorporating
digital health solutions and promoting sustainability. These trends reflect the
industry's commitment to meeting the diverse needs and preferences of women
worldwide while striving to enhance the effectiveness, accessibility, and
overall user experience of female contraceptives. As the global female
contraceptive market continues to evolve, it promises to empower women with
more choices and greater control over their reproductive health,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Female Contraceptive Market By
Contraceptive Drugs (Oral Contraceptives,
Contraceptive Injections, Topical Contraceptives, Spermicides), By Device
(Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges,
Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs),
Others), By
Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Female Contraceptive Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Female
Contraceptive Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com